Jonathan H. Kim

Jonathan H. Kim

Auto-generated profile, based on publicly available information

Jonathan H. Kim

Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2017 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
JKJonathan H. Kim
Jonathan H. Kim
ABAaron L. Baggish
Aaron L. Baggish

1 December 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
JKJonathan H. Kim
Jonathan H. Kim
CHCasey Hollowed
Casey Hollowed
CLChang Liu
Chang Liu
AAAhmed Al-Badri
Ahmed Al-Badri
AAAyman Alkhoder
Ayman Alkhoder
ABAaron L. Baggish
Aaron L. Baggish
Early-life participation in competitive endurance and team-based sports reduces later-life health care utilization and improves longevity.1,2 To what degree this paradigm applies to US football, the most popular team sport in the United States, remains incompletely understood and actively debated.3,4 Mortality studies comparing former US football athletes with the general population document increased cardiovascular (CV) mortality among US football athletes with playing-time body mass index values (calculated as weight in kilograms divided by height in meters squared) greater than 35,5 as well as those that played at a lineman (LM) field position.6 Further, a recent study comparing longevity among former professional baseball vs US football players, a study design that minimized the influence of a healthy-worker effect,7 found higher CV and all-cause mortality among the former US football athletes.8 To date, the CV pathology underlying the inherent risk associated with US football participation remains incompletely understood.

29 November 2024 in The Lancet
Verified
Journal Article
Closed access
JKJonathan H Kim
Jonathan H Kim
MMMatthew W Martinez
Matthew W Martinez
JGJ Sawalla Guseh
J Sawalla Guseh
SKSheela Krishnan
Sheela Krishnan
BGBelinda Gray
Belinda Gray
ABAaron L Baggish
Aaron L Baggish

1 January 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JKJonathan H. Kim
Jonathan H. Kim
SSSalman Sher
Salman Sher
FWFrancis Wang
Francis Wang
BBBrant Berkstresser
Brant Berkstresser
JSJames L. Shoop
James L. Shoop
ABAaron L. Baggish
Aaron L. Baggish

1 October 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JKJonathan H. Kim
Jonathan H. Kim
CHCasey Hollowed
Casey Hollowed
MIMorgan Irwin-Weyant
Morgan Irwin-Weyant
KPKeyur Patel
Keyur Patel
KHKareem Hosny
Kareem Hosny
ABAaron L. Baggish
Aaron L. Baggish

6 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
NMNathaniel Moulson
Nathaniel Moulson
BPBradley J. Petek
Bradley J. Petek
MAMichael J. Ackerman
Michael J. Ackerman
TCTimothy W. Churchill
Timothy W. Churchill
SDSharlene M. Day
Sharlene M. Day
JDJonathan A Drezner
Jonathan A Drezner
Background: Clinical practice recommendations for participation in sports and exercise among young competitive athletes with cardiovascular conditions at risk for sudden death are based largely on expert consensus with a paucity of prospective outcomes data. Recent guidelines have taken a more permissive approach, using a shared decision‐making model. However, the impact and outcomes of this strategy remain unknown. Methods: The ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) study is a prospective, multicenter, longitudinal, observational cohort study designed to monitor clinical outcomes in athletes with potentially life‐threatening cardiovascular conditions. The study will assess sports eligibility decision‐making, exercise habits, psychosocial well‐being, and long‐term cardiovascular outcomes among young competitive athletes with cardiovascular conditions. Competitive athletes aged 18 to <35 years diagnosed with a confirmed cardiovascular condition or borderline finding with potential increased risk of major adverse cardiovascular events are eligible. Outcomes will be monitored for an initial 5‐year follow‐up period or until age 35, and metrics of psychosocial well‐being and composite adverse cardiovascular events including arrhythmias, sudden cardiac arrest/sudden cardiac death, and evidence of disease progression will be compared among athletes who continue versus discontinue competitive sports participation. Conclusions: The ORCCA study aims to assess the process and results of return to sport decision‐making and to monitor major adverse cardiovascular events, exercise habits, and the psychosocial well‐being among young competitive athletes diagnosed with confirmed cardiovascular conditions or borderline findings with potential increased risk of major adverse cardiovascular events. The results of this work will generate an evidence base to inform future guidelines.